Officially Identified the Target Receptor for the Treatment of Neuroblastoma

This article examines Officially Identified the Target Receptor for the Treatment of Neuroblastoma. It presents the main facts, practical implications, and key points in a clearer, easier-to-follow format.

Understanding Officially Identified the Target Receptor for the Treatment of

Previously, Glioblastoma disease was classified by the World Health Organization as the highest level of fibroids, a type of brain tumor that is hard to cure with the average survival rate of patients just over 14 months after detection of the disease.

However, there is a lack of a number of treatments for this disease that effectively motivate researchers to seek other treatments.

Recently, researchers at the Institute of Basic Biology (NIBB) have identified the PTPRZ receptor as an important factor to maintain the properties of stem cells and tumors in glioblastoma cells by targeting target PTPRZ, inhibit glioblastoma C6 tumor cell growth in mice.

The study also showed that the allosteric inhibitor of the PTPRZ receptor known as NAZ2329 can prevent stem cell-like traits from growing and developing in glioblastoma C6 tumor cells.

This finding has just been published in Scientific Reports, and also shows that PTPRZ may be an important target for therapies against glioblastoma in the future.